Theratechnologies Inc. (TH.TO)
| Previous Close | 1.8100 |
| Open | 1.8000 |
| Bid | 1.7900 x 0 |
| Ask | 1.8200 x 0 |
| Day's Range | 1.8000 - 1.8400 |
| 52 Week Range | 1.2200 - 5.8400 |
| Volume | |
| Avg. Volume | 34,132 |
| Market Cap | 83.224M |
| Beta (5Y Monthly) | 1.78 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -1.2600 |
| Earnings Date | Jul 10, 2024 - Jul 15, 2024 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 6.43 |
GlobeNewswireTheratechnologies Announces Mailing of Management Proxy Circular in Connection with its Annual Meeting of Shareholders
MONTREAL, April 15, 2024 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced that the Company has mailed its 2024 management proxy circular to shareholders in connection with its virtual annual meeting of shareholders to be held on May 9, 2024, at 10:00 a.m. ET. Shareholders are encouraged to vote their shares for the propos
- GlobeNewswire
Theratechnologies to Present at the 2024 Bloom Burton & Co. Healthcare Investor Conference
MONTREAL, April 11, 2024 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced that the Company’s President and CEO, Paul Lévesque will be presenting at the 2024 Bloom Burton & Co. Healthcare Investor Conference, which is taking place April 16-17 in Toronto, Canada. Presentation Details: Date/Time:Wednesday, April 17, 2024, at
- GlobeNewswire
Theratechnologies Reports Financial Results and Provides Business Update for First Quarter 2024
Q1 2024 consolidated revenue of $16.2 million Report marks third consecutive quarter of near-flat-to-positive Adjusted EBITDA1FY2024 revenue guidance confirmed between $87 and $90 million and an Adjusted EBITDA in the range of $13-15 millionAcceleration of Phase 1 trial of sudocetaxel zendusortide in advanced ovarian cancer with enrollment of next cohort of patients underway at higher dose level MONTREAL, April 10, 2024 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (“Theratechnologies” or the “Comp
